ICIS

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Principal, PDSB, NCI, Head, Survival, Associate, Incidence, Patient, National Cancer Institute, Cancer, Doctor of Philosophy, Biotechnology, Overalls, Oncology, Neck, ICI, Clinical trial, Immune system, IL-12, ICIS, FDA, Physician, PDS, Food, Pharmaceutical industry

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points: 
  • This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
  • “We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
  • The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
  • The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.

SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Manufacturing, FDA, Health, Pharmaceutical, Oncology, Research, Genetics, Engineering, Science, Clinical Trials, OS, Regeneron Pharmaceuticals, KOSDAQ, Patient, Renal cell carcinoma, Trial of the century, ICI, RCC, CSR, Safety, ICIS

SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).

Key Points: 
  • SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
  • In 2017, SillaJen began a collaboration agreement with Regeneron for the clinical study of Pexa-Vec in combination with cemiplimab in patients with RCC.
  • The study was conducted in four study arms (A to D) to assess the safety and efficacy of the Pexa-Vec in combination with cemiplimab.
  • Given the typically lower response rates in patients with more prior extensive treatments, the results are considered highly encouraging.

ICIS Expands Recycled Plastics Market Coverage with the Launch of Asia R-PP Pricing

Retrieved on: 
Tuesday, April 2, 2024
Managing editor, Pyrolysis, Recycling, Intelligence, PP, Investment, Plastic, ICIS, Plastics

The challenges encountered by both buyers and sellers in the R-PP market highlight the critical need for market insights.

Key Points: 
  • The challenges encountered by both buyers and sellers in the R-PP market highlight the critical need for market insights.
  • By pricing R-PP in Asia, we are providing buyers and sellers with the necessary insights to navigate this evolving landscape efficiently.
  • It brings transparency into contract negotiations, and enhances ICIS' unparalleled portfolio of recycled plastics market intelligence, designed to support the industry's shift towards circular economy models."
  • This marks another significant advancement in ICIS' circular plastics initiatives to address both pricing fluctuations and sourcing complexities in this increasingly important sector.

ICIS Expands Recycled Plastics Market Coverage with the Launch of Asia R-PP Pricing

Retrieved on: 
Tuesday, April 2, 2024
Managing editor, Pyrolysis, Recycling, Intelligence, PP, Investment, Plastic, ICIS, Plastics

The challenges encountered by both buyers and sellers in the R-PP market highlight the critical need for market insights.

Key Points: 
  • The challenges encountered by both buyers and sellers in the R-PP market highlight the critical need for market insights.
  • By pricing R-PP in Asia, we are providing buyers and sellers with the necessary insights to navigate this evolving landscape efficiently.
  • It brings transparency into contract negotiations, and enhances ICIS' unparalleled portfolio of recycled plastics market intelligence, designed to support the industry's shift towards circular economy models."
  • This marks another significant advancement in ICIS' circular plastics initiatives to address both pricing fluctuations and sourcing complexities in this increasingly important sector.

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Retrieved on: 
Thursday, March 28, 2024
Argus Media, Partnership, Bloomberg, ICIS, News, Lubricant, Journalism

LONDON, March 28, 2024 /PRNewswire/ -- ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News , a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market.

Key Points: 
  • LONDON, March 28, 2024 /PRNewswire/ -- ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News , a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market.
  • Through the collaboration, Iain integrates ICIS' extensive content and data resources in Base Oil News market coverage.
  • In return, he contributes market insights to ICIS News , including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers.
  • "It's a very exciting partnership - where we leverage each other's strengths and provide actionable insights to our customers," said Iain Pocock, Founder of Base Oil News.

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Retrieved on: 
Thursday, March 28, 2024
Argus Media, Partnership, Bloomberg, ICIS, News, Lubricant, Journalism

LONDON, March 28, 2024 /PRNewswire/ -- ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News , a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market.

Key Points: 
  • LONDON, March 28, 2024 /PRNewswire/ -- ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News , a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market.
  • Through the collaboration, Iain integrates ICIS' extensive content and data resources in Base Oil News market coverage.
  • In return, he contributes market insights to ICIS News , including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers.
  • "It's a very exciting partnership - where we leverage each other's strengths and provide actionable insights to our customers," said Iain Pocock, Founder of Base Oil News.

ICIS Launches State of Play 2024 Study Providing Comprehensive Insights into the PET Market in Europe

Retrieved on: 
Wednesday, March 27, 2024
Plastic recycling, Waste management, Recycling, PET, RPET, Design, DRS, ICIS, Collection, DFR

Key highlights of the State of Play 2024 study include:

Key Points: 
  • Key highlights of the State of Play 2024 study include:
    PET collection rate in 2022 increased to 60%, from the total of 5 million tonnes of PET resin utilised in the region.
  • "We are excited to present the State of Play 2024 study, a comprehensive analysis of the European PET market.
  • ICIS conducted the study in conjunction with partners, including Plastics Recyclers Europe, Natural Mineral Waters Europe, Petcore Europe, and UNESDA Soft Drinks Europe.
  • For more information on the State of Play 2024 study and to access the full report, visit https://www.plasticsrecyclers.eu/wp-content/uploads/2024/03/PET-Market-i...

ICIS Launches State of Play 2024 Study Providing Comprehensive Insights into the PET Market in Europe

Retrieved on: 
Wednesday, March 27, 2024
Plastic recycling, Waste management, Recycling, PET, RPET, Design, DRS, ICIS, Collection, DFR

Key highlights of the State of Play 2024 study include:

Key Points: 
  • Key highlights of the State of Play 2024 study include:
    PET collection rate in 2022 increased to 60%, from the total of 5 million tonnes of PET resin utilised in the region.
  • "We are excited to present the State of Play 2024 study, a comprehensive analysis of the European PET market.
  • ICIS conducted the study in conjunction with partners, including Plastics Recyclers Europe, Natural Mineral Waters Europe, Petcore Europe, and UNESDA Soft Drinks Europe.
  • For more information on the State of Play 2024 study and to access the full report, visit https://www.plasticsrecyclers.eu/wp-content/uploads/2024/03/PET-Market-i...

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

Retrieved on: 
Wednesday, March 20, 2024
Research, Liver disease, Discovery Science, Growth, Hematology, Patient, Cancer research, AACR, Publication, MSS, Therapy, Translational medicine, PD-L1, ICIS, Hepatotoxicity, Vaccine

Cancer Research, a journal of the American Association for Cancer Research (AACR), publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community.

Key Points: 
  • Cancer Research, a journal of the American Association for Cancer Research (AACR), publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community.
  • In the Cancer Research paper, we present studies used to characterize the differentiated preclinical features and mechanism of action of ATG-101, a tetravalent PD-L1/4-1BB bispecific antibody.
  • "The dedication and relentless efforts of our research team have led to the publication of the preclinical work in the prestigious journal Cancer Research and the development of a new clinical program," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO."
  • [1] ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation.

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Liver, ICIS, FAP, CRC, Mink, MSS, Therapy, Patient, Colorectal cancer, Liver disease, Cancer, Vaccine

MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases.

Key Points: 
  • MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases.
  • This includes the tumor antigens that present due to liver metastases, as the liver shuts down the anti-cancer T cell response.
  • Consequently, liver metastases pose a significant challenge for current pharmacological treatments, including immune checkpoint inhibitors (ICIs).
  • iNKT cells offer promise in overcoming this immune barrier, given their natural ability to reside in and migrate to the liver.